159 related articles for article (PubMed ID: 36290832)
1. Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective.
Tam VC; Ramjeesingh R; Burkes R; Yoshida EM; Doucette S; Lim HJ
Curr Oncol; 2022 Sep; 29(10):7072-7085. PubMed ID: 36290832
[TBL] [Abstract][Full Text] [Related]
2. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
[TBL] [Abstract][Full Text] [Related]
3. A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada.
Ramjeesingh R; Chaudhury P; Tam VC; Roberge D; Lim HJ; Knox JJ; Asselah J; Doucette S; Chhiber N; Goodwin R
Curr Oncol; 2023 Jul; 30(8):7132-7150. PubMed ID: 37622998
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment options for advanced biliary tract carcinoma.
Xie C; McGrath NA; Monge Bonilla C; Fu J
J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
[TBL] [Abstract][Full Text] [Related]
5. Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Oh DY; He AR; Qin S; Chen LT; Okusaka T; Vogel A; Kim JW; Suksombooncharoen T; Lee MA; Kitano M; Burris H; Bouattour M; Tanasanvimon S; McNamara MG; Zaucha R; Avallone A; Tan B; Cundom J; Lee CK; Takahashi H; Ikeda M; Chen JS; Wang J; Makowsky M; Rokutanda N; Żotkiewicz M; Kurland JF; Cohen G; Valle JW
Future Oncol; 2023 Nov; 19(34):2277-2289. PubMed ID: 37746835
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis.
Amonkar MM; Abderhalden LA; Fox GE; Frederickson AM; Grira T; Gozman A; Malhotra U; Malbecq W; Akers KG
Future Oncol; 2024 Apr; 20(13):863-876. PubMed ID: 38353044
[No Abstract] [Full Text] [Related]
7. Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair.
Lamarca A; Barriuso J; McNamara MG; Valle JW
Cancer Treat Rev; 2018 Nov; 70():168-177. PubMed ID: 30218788
[TBL] [Abstract][Full Text] [Related]
8. Unresectable biliary tract cancer: Current and future systemic therapy.
Zhang D; Dorman K; Westphalen CB; Haas M; Ormanns S; Neumann J; Seidensticker M; Ricke J; De Toni EN; Klauschen F; Algül H; Reisländer T; Boeck S; Heinemann V
Eur J Cancer; 2024 May; 203():114046. PubMed ID: 38626513
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for the treatment of biliary tract cancer: an evolving landscape.
Wilbur HC; Azad NS
Ther Adv Med Oncol; 2024; 16():17588359241235799. PubMed ID: 38449562
[TBL] [Abstract][Full Text] [Related]
10. Second-line FOLFOX is not the standard of care for all patients with advanced biliary tract cancer-a commentary from the Young International Society of Geriatric Oncology.
Liposits G; Arora SP; Battisti NML; Soto-Perez-de-Celis E; Loh KP; Williams GR
Ann Oncol; 2023 Jun; 34(6):555-556. PubMed ID: 36813114
[No Abstract] [Full Text] [Related]
11. Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers.
Demir T; Moloney C; Mahalingam D
Crit Rev Oncol Hematol; 2024 May; 199():104388. PubMed ID: 38754771
[TBL] [Abstract][Full Text] [Related]
12. A review of systemic therapy in biliary tract carcinoma.
Jansen H; Pape UF; Utku N
J Gastrointest Oncol; 2020 Aug; 11(4):770-789. PubMed ID: 32953160
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.
Ciardiello D; Maiorano BA; Parente P; Rodriquenz MG; Latiano TP; Chiarazzo C; Pazienza V; Guerrera LP; Amoruso B; Normanno N; Martini G; Ciardiello F; Martinelli E; Maiello E
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055006
[TBL] [Abstract][Full Text] [Related]
14. Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives.
Toledo B; Deiana C; Scianò F; Brandi G; Marchal JA; Perán M; Giovannetti E
Expert Rev Clin Pharmacol; 2024 Apr; 17(4):323-347. PubMed ID: 38413373
[TBL] [Abstract][Full Text] [Related]
15. Response to letter to the editor: Use, response and outcomes of second line chemotherapy in patients with advanced biliary tract cancers.
Mathers B; Abadi S; Davies JM; McIntyre C; Ho C
J Oncol Pharm Pract; 2023 Jun; 29(4):1027. PubMed ID: 36972505
[No Abstract] [Full Text] [Related]
16. New and emerging treatment options for biliary tract cancer.
Noel MS; Hezel AF
Onco Targets Ther; 2013 Oct; 6():1545-52. PubMed ID: 24204165
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?
Boilève A; Hilmi M; Delaye M; Tijeras-Raballand A; Neuzillet C
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070929
[TBL] [Abstract][Full Text] [Related]
18. Contemporary Tailored Oncology Treatment of Biliary Tract Cancers.
Turkes F; Carmichael J; Cunningham D; Starling N
Gastroenterol Res Pract; 2019; 2019():7698786. PubMed ID: 31929787
[TBL] [Abstract][Full Text] [Related]
19. The potential of patient-derived organoids in precision medicine of biliary tract cancer.
Yáñez-Bartolomé M; Macarulla T; Tian TV
Cell Rep Med; 2023 Nov; 4(11):101294. PubMed ID: 37992681
[TBL] [Abstract][Full Text] [Related]
20. Liquid biopsy in biliary tract cancer from blood and bile samples: current knowledge and future perspectives.
Arrichiello G; Nacca V; Paragliola F; Giunta EF
Explor Target Antitumor Ther; 2022; 3(3):362-374. PubMed ID: 36045913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
